ACA subsidies expanded, PBM kickbacks exposed, broker fraud crackdown

What it does

This bill extends and expands the Affordable Care Act's premium tax credits (subsidies) for health insurance through 2027, making coverage more affordable for lower-income households. It also tightens oversight of insurance agents and brokers to prevent fraud, requires pharmacy benefit managers (PBMs) to disclose pricing details and eliminate hidden kickbacks, and extends the ACA's open enrollment period for 2026.

Why we flagged it

The bill's core mechanisms are (1) extending and expanding ACA premium subsidies to lower costs for enrollees, and (2) imposing transparency and anti-fraud rules on insurance intermediaries. Both serve public health and consumer protection, not narrow private interests.

What the text implies

• PBM transparency rules may increase administrative costs for insurers and PBMs, which could be passed to employers or enrollees in the long term, offsetting some premium savings.
• The bill's reliance on Death Master File checks to remove deceased enrollees may create privacy concerns if the matching process is imperfect or if data is mishandled.
• Expanded subsidies for households up to 700% of poverty line (roughly $180k for a family of four) may shift costs to higher-income unsubsidized enrollees or taxpayers.
• Agent and broker penalties ($10k–$200k per violation, plus criminal liability) may reduce the supply of enrollment assistance in rural or underserved areas if smaller brokers exit the market.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people gain lower insurance premiums through expanded subsidies and protection against broker fraud and hidden PBM markups. The transparency and audit provisions reduce the risk that intermediaries will exploit enrollees through undisclosed fees or steering to higher-cost plans.

Who stands to gain

• Low- and moderate-income households (premium subsidy expansion)
• Enrollees in ACA plans (fraud prevention, transparency)
• Pharmacies (PBM transparency may improve reimbursement visibility)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), Pharmacy Benefit Managers (PBMs), Insurance agents and brokers, PDP sponsors (prescription drug plan sponsors), Medicare Advantage organizations, Qualified Health Plan issuers, ACA Exchanges, Social Security Administration (Death Master File)

Where it stands

22 cosponsors: 13 Republicans, 9 Democrats.

• Dec 9, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 9, 2025 — Referred to House Committee on Education and Workforce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 7 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $5,480,000 in lobbying spend. A filing names 20 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Brian Fitzpatrick, the sponsor, reported $2,362,211 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• Healthequity, Inc. — $1,190,000 on 2 filings
• Highmark Inc — $380,000 on 2 filings
• National Association of Chain Drug Stores — $290,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.